Specialty Pharmaceuticals and Patient Privacy
In the specialty pharmaceutical industry, patient privacy is crucial. Privacy can be a challenge for companies looking to gather and consolidate patient information from various sources. The de-identification of that information is critical to unlocking the ability to use this data to make smarter business decisions and enhance drug development.
De-identifying data can provide pharmaceutical companies with a variety of benefits, including:
- The ability to assess the value and effectiveness of a drug
- Provide improved support for patients
- Enhance research and contribute to new breakthroughs
Read our white paper to learn how de-identifying data can help biopharmaceutical companies tap into the broad base of evidence required to support and grow business, while maintaining patient privacy.
To download the white paper, please complete the form to the right
You might also like:
GDPR and Anonymization
Pushing the idea of anonymization to the forefront is the European Parliament with the new regulation – General Data Protection…
Comparing Pseudonymization and Anonymization
Comparing Under the GDPR In May 2018, the General Data Protection Regulation (GDPR) will come into effect, establishing a new…
De-identification 101, your primer on protecting health information (PHI).
Gain further insight into de-identification protocols with this Privacy by Design/Privacy Analytics white paper.